Use of postmenopausal hormone replacement therapy and risk of non-Hodgkin's lymphoma: a Danish Population-based Cohort Study by Nørgaard, M et al.
Use of postmenopausal hormone replacement therapy and risk of
non-Hodgkin’s lymphoma: a Danish Population-based Cohort
Study






3 and HT Sørensen
1
1Department of Clinical Epidemiology, Aarhus University Hospital, Sdr. Skovvej 15, Postbox 365, DK-9100 Aalborg, Denmark;
2Institute of Cancer
Epidemiology, Danish Cancer Society, DK-2100 Copenhagen, Denmark;
3Department of Haematology, Aalborg Hospital, Aarhus University Hospital,
DK-9000 Aalborg, Denmark and
4Department of Oncology, Aalborg Hospital, Aarhus University Hospital, DK-9000 Aalborg, Denmark
Use of postmenopausal hormone replacement therapy (HRT) has been hypothesised to be associated with a reduced risk of non-
Hodgkin’s lymphoma (NHL), but the epidemiologic evidence is conflicting. To examine the risk of NHL in HRT users aged 40 and
older, we conducted a cohort study in the County of North Jutland, Denmark (population 0.5million) using data from population-
based health registries for the period 1989–2002. We computed age-standardised NHL incidence rates and used Cox regression
analysis to compute the relative risk (RR) and corresponding 95% confidence intervals (CI) of NHL among HRT users compared with
non-users, adjusting for age and calendar period. The number of prescriptions redeemed (1, 2–4, 5–9, 10–19, or 20 or more
prescriptions) was used as a proxy for duration of HRT. We identified 40 NHL cases among HRT users during 179838 person-years
of follow-up and 310 NHL cases among non-users during 1247302 person-years of follow-up. The age-standardised incidence rates
of NHL were 25.7 per 100000 among HRT users and 24.2 per 100000 among non-users, yielding an adjusted RR of 0.99 (95% CI:
0.71–1.39). Our data did not support an association between HRT use and risk of NHL.
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The incidence of non-Hodgkin’s lymphoma (NHL) has increased
dramatically during the past 50 years in most Western countries
(Hjalgrim et al, 1996; Zinzani, 2005). Established risk-factors, such
as immunosuppresion, autoimmunity, and HIV infection account
for only a small fraction of cases (Adami et al, 2002). Men are
reported to have a higher incidence rates of NHL than women. In
Denmark age-standardised incidence rates (based on the World
Standard population) in the year 2000 were nine per 100000 in
men and seven per 100000 in women (Danish Board of Health,
2004), and this difference may suggest a protective impact of
female sex hormones. Supposedly, oestrogen and progesterone
play a role in modulation of the immune system (Forsberg, 1984;
Medina et al, 2000), but the mechanism is not clear.
Hormone replacement therapy (HRT) with oestrogens, with or
without progestin, for menopausal symptoms has been associated
with a decreased risk of Hodgkin’s disease (Glaser et al, 2003).
However, studies of HRT use and risk of NHL are few (Tavani et al,
1997; Nelson et al, 2001; Cerhan et al, 2002) and with varying
results. We therefore conducted a cohort study using a population-
based prescription database available in North Jutland, Denmark
and the Danish Cancer Registry.
MATERIALS AND METHODS
Study population
We conducted this cohort study in North Jutland County,
Denmark, which has nearly 500000 inhabitants (approximately
9% of the Danish population). Using the files of the Civil
Registration System, which includes all County residents, we
identified 157024 women aged 40 or older at any time in the
period 1 January 1989 to 31 December 2002. The cohort comprised
149132 women following exclusion of two groups: women with
documented HRT use before the age of 40 (n¼880) identified
through linkage with the Pharmaco-Epidemiologic Prescription
Database (see below); and women with a history of cancer (except
nonmelanoma skin cancer) before study entry (pre-1989 or under
the age of 40 years, n¼7012), identified through linkage with the
Danish Cancer Registry. The Danish Cancer Registry has recorded
incident cases of cancer on a nationwide basis since 1943 and has
been shown to have accurate and virtually complete ascertainment
of cancer cases (Storm et al, 1997).
Assessment of HRT use
The National Health Service (NHS) in Denmark provides tax-
supported free health care for all inhabitants, guaranteeing free
access to general practitioners and hospitals; the NHS refunds a
varying proportion of costs of medication prescribed by physicians
through a computerised accounting system. In North Jutland
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yCounty, this accounting system also serves as the source of data for
the Pharmaco-Epidemiologic Prescription Database, which was
initiated in 1989 and covered all pharmacies in the county by 1991
(Gaist et al, 1997). This database includes the customer’s civil
registration number (a unique number assigned to all Danish
residents that encodes gender and date of birth), the type and
amount of drug prescribed according to the Anatomical Ther-
apeutical Chemical (ATC) classification system, and the date the
drug was dispensed. We used the prescription database to identify
all prescriptions of HRT (ATC codes: G03A, G03C, G03D and
G03F) during the study period. In Denmark, costs for oral
contraceptives used for contraception are not reimbursed. Women
who do receive reimbursement for the costs of oral contraceptives
are using the medication for purposes other than contraception.
This group of women was included in the study. Prescription of
topical HRT was not included. We also retrieved information on
prescriptions for sex hormones in addition to those used in the
traditional HRT definition including androgens, antiandrogens,
androgen antagonists and clomiphene (ATC codes: G03B, G03G,
G03H and G03X).
Information on NHL
Linkage to the Danish Cancer Registry (Storm et al, 1997) allowed
us to identify cases of NHL diagnosed between 1 January 1989 and
31 December 2002 among women aged 40 and older. Follow-up to
identify cases of NHL continued until the date of an NHL
diagnosis, the date of a cancer diagnosis other than NHL (except
nonmelanoma skin cancer), the date of a reimbursed prescription
for non-HRT sex hormones, the date of death, the date of
migration, or 31 December 2002, whichever came first.
Data analysis
We computed age-standardised NHL incidence rates (standardised
to the age distribution of the base population) as well as age-
standardised NHL incidence rate ratios, defined as the NHL
incidence rate for women using HRT divided by the NHL
incidence rate for non-users. In addition, we used Cox’s regression
analysis to compute the hazard ratio as a measure of relative risk
(RR) and associated 95% confidence intervals (CI) of NHL among
HRT users compared with non-users, adjusting for age and
calendar period. Hormone replacement therapy use was cate-
gorised into five groups based on number of prescriptions
redeemed (1 prescription, 2–4 prescriptions, 5–9 prescriptions,
10–19 prescriptions, and 20 or more prescriptions) (Ewertz et al,
2005). We further stratified follow-up time according to years since
the last HRT-prescription (less than 2, 2–5, and more than 5
years). Over time, the model allowed subjects to change between
categories of covariates and exposure variables. Within each
categorical level all variables were treated as time-independent.
RESULTS
Among 23708 HRT users we identified 40 NHL cases during a
combined follow-up period of 179838 person-years. Among
125424 non-users, we identified 310 NHL cases during 1247302
person-years of follow-up. Age-standardised incidence rates of
NHL were 25.7 per 100000 person-years among HRT users and
24.2 per 100000 person-years among non-users, yielding an age-
standardised rate ratio of 1.06 (95% CI: 0.761.44). After adjusting
for calendar period, the RR was 0.99 (95% CI: 0.71–1.39).
After stratifying by number of prescriptions, we found no
substantial indication of decreased risk of NHL associated with
HRT use. Age-standardised NHL rate ratios were 0.99 (95% CI:
0.36–2.16) among patients with one HRT prescription and 0.95
(95% CI: 0.47–1.69) among patients with more than 20 HRT
prescriptions. Similarly, the adjusted RR estimates according to
number of prescriptions were 0.91 (95% CI: 0.41–2.05) for one
prescription, and 0.98 (95% CI: 0.53–1.80) for more than 20
prescriptions. In addition, we observed no trends in RR estimates
with time since the last redeemed prescription (Table 1).
Among the 40 HRT exposed NHL cases four were classified as
follicular lymphomas compared with 38 follicular lymphomas
among the 310 unexposed NHL cases, yielding an adjusted RR on
0.56 (95% CI: 0.20–1.61). For large B-cell lymphoma the adjusted
RR was 0.57 (95% CI: 0.27–1.18) based on 8 cases of large B-cell
lymphomas among HRT users and 103 among non-users.
DISCUSSION
This large population-based cohort study did not indicate any
substantial association between HRT use and NHL risk. In
contrast, an American case–control study involving 177 cases
with intermediate- or high-grade B-cell NHL and 177 community
controls found a decreased risk of NHL associated with HRT use
(OR 0.64 (95% CI: 0.32–1.29)) (Nelson et al, 2001). These findings
accorded with an Italian case-control study involving 145 NHL
cases and 361 hospital controls, in which ‘ever use’ of HRT was
associated with a decreased risk of NHL compared with ‘never use’
(OR 0.7 (95% CI: 0.3–1.4)) (Tavani et al, 1997). On the other hand,














Unexposed 310 1247302 24.2 Reference Reference
HRT-exposed (1+ prescriptions) 40 179838 25.7 1.06 (0.76–1.44) 0.99 (0.71–1.39)
Recency
o2 years since latest prescription 25 119914 22.9 0.95 (0.61–1.40) 0.98 (0.65–1.49)
2–5 years since latest prescription 6 33127 22.5 0.93 (0.34–2.03) 0.78 (0.35–1.76)
45 years since latest prescription 9 26796 30.5 1.26 (0.58–2.39) 1.24 (0.63–2.42)
Number of HRT prescriptions
1 6 29292 24.0 0.99 (0.36–2.16) 0.91 (0.41–2.05)
2–4 5 37507 16.0 0.66 (0.22–1.55) 0.63 (0.26–1.52)
5–9 8 32437 34.7 1.43 (0.62–2.83) 1.16 (0.57–2.35)
10–19 10 35463 33.2 1.37 (0.66–2.52) 1.31 (0.69–2.48)
20+ 11 45139 22.9 0.95 (0.47–1.69) 0.98 (0.53–1.80)
aAdjusted for age and calendar period.
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ythe Iowa Women’s Health Study Cohort, which included 37220
women and a total of 258 NHL cases, found that current HRT users
were at increased risk of NHL (RR 1.4 (95% CI: 0.9–2.0). This
association, however, was only seen in patients with follicular NHL
(RR 3.3 (95% CI: 1.6–6.9)) and no associations were found
between HRT use and risk of diffuse NHL (RR 1.1 (95% CI: 0.6–
2.0)) or small lymphocytic NHL (RR 0.6 (95% CI: 0.1–2.7))
(Cerhan et al, 2002).
A number of reproductive factors have been studied in relation
to NHL. In the Italian case–control study, the ORs of NHL by
number of pregnancies, abortions, births, age at first birth, and
time since last birth were all close to unity (Tavani et al, 1997).
Adami et al (1997) found that associations between parity and
NHL risk were weak – if they existed at all – and concluded that
changes in reproductive patterns are unlikely to contribute to the
increase in NHL. On the basis of our current findings, we can
extend this conclusion to postmenopausal HRT use.
The main strengths of our study were its relatively large size and
a well-defined geographical area, for which standardised popula-
tion-based information was available on exposure as well as
outcome variables. Exposure data included a full history of
prescriptions for HRT during the study period. As HRT is only
available by prescription in Denmark, we have probably captured
virtually all women exposed to HRT in the study population during
the follow-up period (Løkkegaard et al, 2004).
A potential study weakness is the lack of information on
compliance in taking the prescribed medications. However, a
comprehensive validation study in our setting, regarding self-
reported HRT use among Danish nurses, found that more than
82% of those recorded in the database as ever-users reported
having used HRT (Løkkegaard et al, 2004). Moreover, most of the
patients in our study redeemed more than one prescription, and
no substantial association was found between HRT use and risk of
NHL even among patients who had redeemed more than 20
prescriptions.
The lacking information on other potentially confounding
factors such as immunosuppresion, autoimmunity, and HIV
infection was also a limitation (Levine and Hoover, 1992;
Bhaskaran et al, 2004; Askling et al, 2005). Given the low
prevalence of these diseases, however, their possible confounding
effect is unlikely to have influenced the results substantially. We
also lacked information about lifestyle and environmental
exposures. In studies of HRT and primary prevention of
cardiovascular disease, discordant results have been found
between observational data and prevention trials (Humphrey
et al, 2002). As a possible explanation for these discordant
results selection bias and particularly healthy user bias has been
suggested (Humphrey et al, 2002). It is possible that women
with medical or psychiatric problems are less likely to receive
HRT, and that women who are prescribed HRT are in better
overall health, which could be associated with a decreased risk
of lymphoma. We cannot rule out that this selection bias may
have caused us to underestimate the effect of HRT. In North
Jutland County, there is no strong association between the use
of HRT and socioeconomic status (Olesen et al, 2005), and
therefore we do not expect important confounding by socio-
economic status.
In conclusion, our data did not support any important
association between HRT use and risk of NHL.
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